Solopharm is taking part in the 32nd International Professor Yuri Astakhov «White Nights» Ophthalmology Congress – one of the largest scientific and practical events in the field of ophthalmology, which will be held in St. Petersburg from May 25 to 29.
The «White Nights» Congress is not just a platform for knowledge exchange, but a focal point for the current scientific and clinical agenda. Key challenges of modern ophthalmology are discussed here, ranging from the increasing visual load on patients to the introduction of new therapeutic approaches and treatment technologies. The event is attended by leading Russian and international experts, fostering a professional dialogue at the intersection of science, practice, and the pharmaceutical industry.
For Solopharm, participating in the congress is an opportunity to maintain a professional dialogue with the medical community, discuss modern therapeutic approaches, and present solutions developed with the real needs of practitioners in mind.
The name of Professor Yuri Astakhov holds special significance for the company. During the early development of its ophthalmology division, Professor Astakhov advised Solopharm on the creation of its first ophthalmic drugs. This collaboration helped the company build its direction from the very start in close connection with clinical practice, modern scientific approaches, and the current needs of the medical community.
Furthermore, Solopharm greatly values the opportunity for direct interaction with physicians at the congress – discussing clinical experience, receiving feedback on the use of its products, and understanding physicians’ expectations from modern therapy. Such dialogue allows the company not only to follow trends, but to develop products that are truly in demand and effective in practice.
Comment from the Solopharm Press Center:
«For us, it is important to be not only a manufacturer but also a full-fledged member of the professional community. The «White Nights» Congress is an opportunity to listen to physicians, discuss current challenges, and align our development direction. The foundation of our work is drug quality and their real-world effectiveness for patients – and platforms like this help us constantly keep that focus.»
